These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 28472509)

  • 1. Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.
    Thomas AA; Abrey LE; Terziev R; Raizer J; Martinez NL; Forsyth P; Paleologos N; Matasar M; Sauter CS; Moskowitz C; Nimer SD; DeAngelis LM; Kaley T; Grimm S; Louis DN; Cairncross JG; Panageas KS; Briggs S; Faivre G; Mohile NA; Mehta J; Jonsson P; Chakravarty D; Gao J; Schultz N; Brennan CW; Huse JT; Omuro A
    Neuro Oncol; 2017 Oct; 19(10):1380-1390. PubMed ID: 28472509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131.
    Vogelbaum MA; Hu C; Peereboom DM; Macdonald DR; Giannini C; Suh JH; Jenkins RB; Laack NN; Brachman DG; Shrieve DC; Souhami L; Mehta MP
    J Neurooncol; 2015 Sep; 124(3):413-20. PubMed ID: 26088460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.
    Speirs CK; Simpson JR; Robinson CG; DeWees TA; Tran DD; Linette G; Chicoine MR; Dacey RG; Rich KM; Dowling JL; Leuthardt EC; Zipfel GJ; Kim AH; Huang J
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):268-76. PubMed ID: 25636755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.
    Ahluwalia MS; Xie H; Dahiya S; Hashemi-Sadraei N; Schiff D; Fisher PG; Chamberlain MC; Pannullo S; Newton HB; Brewer C; Wood L; Prayson R; Elson P; Peereboom DM
    J Neurooncol; 2015 Mar; 122(1):111-9. PubMed ID: 25534576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma.
    Mikkelsen T; Doyle T; Anderson J; Margolis J; Paleologos N; Gutierrez J; Croteau D; Hasselbach L; Avedissian R; Schultz L
    J Neurooncol; 2009 Mar; 92(1):57-63. PubMed ID: 19011763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.
    Brandes AA; Tosoni A; Cavallo G; Reni M; Franceschi E; Bonaldi L; Bertorelle R; Gardiman M; Ghimenton C; Iuzzolino P; Pession A; Blatt V; Ermani M;
    J Clin Oncol; 2006 Oct; 24(29):4746-53. PubMed ID: 16954518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131.
    Vogelbaum MA; Berkey B; Peereboom D; Macdonald D; Giannini C; Suh JH; Jenkins R; Herman J; Brown P; Blumenthal DT; Biggs C; Schultz C; Mehta M
    Neuro Oncol; 2009 Apr; 11(2):167-75. PubMed ID: 18779504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors.
    Gan HK; Rosenthal MA; Dowling A; Kalnins R; Algar E; Wong N; Benson A; Woods AM; Cher L
    Neuro Oncol; 2010 May; 12(5):500-7. PubMed ID: 20406900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
    Kouwenhoven MC; Kros JM; French PJ; Biemond-ter Stege EM; Graveland WJ; Taphoorn MJ; Brandes AA; van den Bent MJ
    Eur J Cancer; 2006 Oct; 42(15):2499-503. PubMed ID: 16914310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience.
    Frenel JS; Leux C; Loussouarn D; Le Loupp AG; Leclair F; Aumont M; Mervoyer A; Martin S; Denis MG; Campone M
    J Neurooncol; 2013 Aug; 114(1):85-91. PubMed ID: 23681562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression and Their Prognostic Roles in 41 Turkish Anaplastic Oligodendroglioma Patients.
    Hacisalihoglu P; Kucukodaci Z; Gundogdu G; Bilgic B
    Turk Neurosurg; 2017; 27(5):682-689. PubMed ID: 27651340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
    Baumert BG; Hegi ME; van den Bent MJ; von Deimling A; Gorlia T; Hoang-Xuan K; Brandes AA; Kantor G; Taphoorn MJB; Hassel MB; Hartmann C; Ryan G; Capper D; Kros JM; Kurscheid S; Wick W; Enting R; Reni M; Thiessen B; Dhermain F; Bromberg JE; Feuvret L; Reijneveld JC; Chinot O; Gijtenbeek JMM; Rossiter JP; Dif N; Balana C; Bravo-Marques J; Clement PM; Marosi C; Tzuk-Shina T; Nordal RA; Rees J; Lacombe D; Mason WP; Stupp R
    Lancet Oncol; 2016 Nov; 17(11):1521-1532. PubMed ID: 27686946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and prognostic value of molecular markers.
    Minniti G; Arcella A; Scaringi C; Lanzetta G; Di Stefano D; Scarpino S; Pace A; Giangaspero F; Osti MF; Enrici RM
    J Neurooncol; 2014 Jan; 116(2):275-82. PubMed ID: 24162810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
    Anand S; Chatterjee A; Gupta T; Panda P; Moiyadi A; Epari S; Patil V; Krishnatry R; Goda JS; Jalali R
    World Neurosurg; 2021 Oct; 154():e176-e184. PubMed ID: 34245877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative molecular analysis of primary and recurrent oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation: a case report.
    Ono T; Reinhardt A; Takahashi M; Nanjo H; Kamataki A; von Deimling A; Shimizu H
    Acta Neurochir (Wien); 2020 Dec; 162(12):3019-3024. PubMed ID: 32785787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature.
    Sorge C; Li R; Singh S; Reddy AT; Solomon DA; Perry A; Friedman GK
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28696020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial.
    Taliansky-Aronov A; Bokstein F; Lavon I; Siegal T
    J Neurooncol; 2006 Sep; 79(2):153-7. PubMed ID: 16855865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas.
    Jiang H; Ren X; Cui X; Wang J; Jia W; Zhou Z; Lin S
    Neuro Oncol; 2013 Jun; 15(6):775-82. PubMed ID: 23486687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
    Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
    Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
    Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
    J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.